摘要
经典名方百合地黄汤经化裁可用于多种病因所致抑郁,但目前多为基础理论研究或临床研究,缺乏对其活性成分及其作用机制的研究。该文以经典名方百合地黄汤为研究对象,借助中药整合药理学平台（TCMIP）探讨其活性成分、作用靶点和作用机制。该研究共预测得到10个活性成分,其中百合成分4个,分别为6-O-β-D-吡喃葡萄糖基-3β,26-二羟基-Δ5-胆甾烯-16,22-二氧代-3-O-α-L-吡喃鼠李糖基-（1→2）-β-D-吡喃葡萄糖苷、岷江百合苷D、百合皂苷、百合苷C;地黄成分6个,分别为谷氨酸、蔗糖、苍耳苷、腺苷、L-精氨酸、甘露三糖。其作用机制涉及54个关键药靶及嘌呤代谢、氨基酸代谢障碍、神经营养因子、雌激素信号通路等相关生物过程和代谢通路。这些靶点及通路均与文献报道的抑郁症发病机制相吻合,证明TCMIP在预测中药及复方作用机制方面具有较高的准确性。此外,研究还显示百合地黄汤在帕金森病、抗肿瘤、儿童急性白血病的治疗中存在一定的应用价值。该研究为进一步研究百合地黄汤抗抑郁作用机制提供科学依据,同时为经典名方的研究提供了新的研究思路。
The classical traditional Chinese medicine excellent prescriptions（ c TCMe P） of Baihe Dihuang decoction can be used for the depression caused by a variety of causes,but at present,most of them are only in theoretical research or clinical research,and lack of research on their active ingredients and action mechanism. In this study,the integrative pharmacology of traditional Chinese medicine（ TCMIP,www. tcmip. cn） was used to explore the active ingredients,targets and the mechanisms of Baihe Dihuang decoction.Based on the TCMIP,a total of 10 active ingredients were predicted,including 4 from Lilium brownii： 26-O-β-D-glucopyranosyl-3β,26-dihydroxy-Δ5-choleslen-16,22-dioxo-3-O-α-L-rhamnopyranosyl-（ 1 →2）-β-D-glucopyranoside,regaloside D,brownioside and lilioside C; 6 from Radix Rehmannia： alanine,sucrose,strumaroside,adenosine,L-arginine and manninotriose. Fifty five targets and multiple biological processes and metabolic pathways such as purine metabolism,disorder of amino acid catabolism,neurotrophic factors,and estrogen signaling pathway were involved in the mechanism. These targets and pathways were consistent with the pathogenesis of depression in other literature,proving that TCMIP had high accuracy in predicting the action mechanism of TCM and compound prescriptions. In addition,the study also showed that Baihe Dihuang decoction had certain application value for the treatment of Parkinson＇ s disease,anti-tumor,and childhood acute leukemia. This study would provide a scientific basis for further studies on the mechanism of Baihe Dihuang decoction in the treatment of depression,and provide a new research idea for the study of c TCMe P.
作者
彭修娟
杨新杰
陈衍斌
逯莉
许海燕
许海玉
丁腾
刘峰
PENG Xiu-juan;YANG Xin-jie;CHEN Yan-bin;LU Li;XU Hai-yan;XU Hai-yu;DING Teng;LIU Feng(Shaanxi Institute of luternational Trade ＆ Commerce, Xianyang 712046, China;Shaanxi University of Chinese Medicine, Xianyang 712046, China;Shaanxi Buchang Pharmaceutical Co. , Ltd. , Xi＇an 710075, China;Institute of Chinese Muteria Mediea, China Academy of Chinese Medical Sciences, Beijing 100700, China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2018年第7期1338-1344,共7页
China Journal of Chinese Materia Medica
基金
国家“重大新药创制”科技重大专项(2018ZX09721005-009-013)
